Written Question·Department of Health and Social Care·UIN 69551
Trastuzumab Deruxtecan
Tabled: 21 July 2025
Answered: 1 September 2025
Question
Helen Maguire
Liberal Democrat — Epsom and Ewell
To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential impact of NICE’s rejection of trastuzumab deruxtecan for use in secondary breast cancer treatment on patient outcomes.
Answer
Karin SmythDecisions on whether new medicines should be routinely funded by the National Health Service in England are made on the basis of recommendations from the National Institute for Health and Care Excellence (NICE) following an evaluation of a treatment’s cos...
ⓘ
This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 69551) →